INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 45h ago
HOUSE PTR5h ago
SEC 13F5h ago
ROBINHOOD CHAIN5h ago
Public company

RGENREPLIGEN CORP

CIK 0000730272

EDGAR filingsOpen in network
Disclosed transactions9
Buys / sells0 / 2
Max Insider Score18
Connections4with evidence

RGEN · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
13
DR
Douglass Brian RobbCHIEF PRODUCT OFFICER
RGENREPLIGEN CORP
Grant or award
A—
700 sh
Oct 6, 2026Oct 8, 2026
traded Oct 6, 2026
+2dSEC FORM 4

Evidence

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 2836 · Biological Products, (No Diagnostic Substances) · Nov 4, 2026
  • ← Insider ofevidence
    Douglass Brian RobbCHIEF PRODUCT OFFICER · Oct 8, 2026
  • ← Insider ofevidence
    Garland Jason KCFO · Sep 28, 2026
  • ← Insider ofevidence
    Loeillot OlivierDirector, Chief Executive Officer · Sep 25, 2026
9
DR
Douglass Brian RobbCHIEF PRODUCT OFFICER
RGENREPLIGEN CORP
Grant or award
A
—
675 sh
Oct 6, 2026
Oct 8, 2026
traded Oct 6, 2026
+2d
SEC FORM 4

Evidence

12
GK
Garland Jason KCFO
RGENREPLIGEN CORP
Tax withholding
F$80K
421 sh
Sep 25, 2026Sep 28, 2026
traded Sep 25, 2026
+3dSEC FORM 4

Evidence

9
LO
Loeillot OlivierDirector, Chief Executive Officer
RGENREPLIGEN CORP
Option exercise · 10b5-1 plan
M$706K
4,542 sh
Sep 24, 2026Sep 25, 2026
traded Sep 24, 2026
+1dSEC FORM 4

Evidence

15
LO
Loeillot OlivierDirector, Chief Executive Officer
RGENREPLIGEN CORP
Open-market sale · 10b5-1 plan
SELL$863K
4,542 sh
Sep 24, 2026Sep 25, 2026
traded Sep 24, 2026
+1dSEC FORM 4

Evidence

11
LO
Loeillot OlivierDirector, Chief Executive Officer
RGENREPLIGEN CORP
Option exercise · 10b5-1 plan
M—
8,404 sh
Sep 24, 2026Sep 25, 2026
traded Sep 24, 2026
+1dSEC FORM 4

Evidence

11
LO
Loeillot OlivierDirector, Chief Executive Officer
RGENREPLIGEN CORP
Option exercise · 10b5-1 plan
M—
4,542 sh
Sep 24, 2026Sep 25, 2026
traded Sep 24, 2026
+1dSEC FORM 4

Evidence

12
LO
Loeillot OlivierDirector, Chief Executive Officer
RGENREPLIGEN CORP
Option exercise · 10b5-1 plan
M$1.30M
8,404 sh
Sep 24, 2026Sep 25, 2026
traded Sep 24, 2026
+1dSEC FORM 4

Evidence

18
LO
Loeillot OlivierDirector, Chief Executive Officer
RGENREPLIGEN CORP
Open-market sale · 10b5-1 plan
SELL$1.60M
8,404 sh
Sep 24, 2026Sep 25, 2026
traded Sep 24, 2026
+1dSEC FORM 4

Evidence